175 related articles for article (PubMed ID: 25539414)
1. Current opinion on bevacizumab on endometrial cancer treatment.
Bogliolo S; Cassani C; Gardella B; Musacchi V; Babilonti L; Venturini PL; Ferrero S; Spinillo A
Expert Opin Biol Ther; 2015 Feb; 15(2):299-307. PubMed ID: 25539414
[TBL] [Abstract][Full Text] [Related]
2. Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.
Papa A; Zaccarelli E; Caruso D; Vici P; Benedetti Panici P; Tomao F
Expert Opin Investig Drugs; 2016; 25(1):31-49. PubMed ID: 26560489
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab in endometrial cancer treatment.
Morotti M; Valenzano Menada M; Venturini PL; Ferrero S
Expert Opin Biol Ther; 2012 May; 12(5):649-58. PubMed ID: 22428875
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab for the treatment of cervical cancer.
Bizzarri N; Ghirardi V; Alessandri F; Venturini PL; Valenzano Menada M; Rundle S; Leone Roberti Maggiore U; Ferrero S
Expert Opin Biol Ther; 2016; 16(3):407-19. PubMed ID: 26796332
[TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
Minion LE; Tewari KS
Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis as a therapeutic target in breast cancer.
Koutras AK; Starakis I; Lymperatou D; Kalofonos HP
Mini Rev Med Chem; 2012 Oct; 12(12):1230-8. PubMed ID: 22512568
[TBL] [Abstract][Full Text] [Related]
8. A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy.
Kong DH; Kim MR; Jang JH; Na HJ; Lee S
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28817103
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
Kamat AA; Merritt WM; Coffey D; Lin YG; Patel PR; Broaddus R; Nugent E; Han LY; Landen CN; Spannuth WA; Lu C; Coleman RL; Gershenson DM; Sood AK
Clin Cancer Res; 2007 Dec; 13(24):7487-95. PubMed ID: 18094433
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab treatment of prostate cancer.
Small AC; Oh WK
Expert Opin Biol Ther; 2012 Sep; 12(9):1241-9. PubMed ID: 22775507
[TBL] [Abstract][Full Text] [Related]
11. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
[TBL] [Abstract][Full Text] [Related]
12. Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer.
Rauh-Hain JA; Guseh SH; Esselen KM; Growdon WB; Schorge JO; Horowitz NS; Krasner CN; del Carmen MG; Birrer MJ; Dizon DS
Int J Gynecol Cancer; 2013 Sep; 23(7):1219-25. PubMed ID: 23975042
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in the treatment of breast cancer.
Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab for the treatment of high-grade glioma.
Khasraw M; Simeonovic M; Grommes C
Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
[TBL] [Abstract][Full Text] [Related]
15. Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance.
Davies S; Dai D; Pickett G; Thiel KW; Korovkina VP; Leslie KK
Oncol Rep; 2011 Mar; 25(3):855-62. PubMed ID: 21240464
[TBL] [Abstract][Full Text] [Related]
16. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Heist RS; Duda DG; Sahani DV; Ancukiewicz M; Fidias P; Sequist LV; Temel JS; Shaw AT; Pennell NA; Neal JW; Gandhi L; Lynch TJ; Engelman JA; Jain RK
Proc Natl Acad Sci U S A; 2015 Feb; 112(5):1547-52. PubMed ID: 25605928
[TBL] [Abstract][Full Text] [Related]
17. Endometrial cancer: Molecular markers and management of advanced stage disease.
Arend RC; Jones BA; Martinez A; Goodfellow P
Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis as targeted breast cancer therapy.
Hayes DF; Miller K; Sledge G
Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641
[TBL] [Abstract][Full Text] [Related]
19. Issues and promises of bevacizumab in prostate cancer treatment.
Cereda V; Formica V; Roselli M
Expert Opin Biol Ther; 2018 Jun; 18(6):707-717. PubMed ID: 29781343
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF therapy with bevacizumab for anterior segment eye disease.
Hosseini H; Nowroozzadeh MH; Salouti R; Nejabat M
Cornea; 2012 Mar; 31(3):322-34. PubMed ID: 22157572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
